BMS sees success in Phase III Sotyktu psoriatic arthritis trials

December 23, 2024

Bristol Myers Squibb announced positive Phase III results for Sotyktu (deucravacitinib) in psoriatic arthritis, showing greater treatment response compared to placebo. Sotyktu, an oral TYK2 inhibitor, is approved for plaque psoriasis and saw $170m in sales in 2023, projected to rise to $2.2bn by 2030.

Related Clinical Trials

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

Highlighted Terms

US Food and Drug Administration GlobalData Bristol Myers Squibb TNFα inhibitor Takeda plaque psoriasis American College of Rheumatology Sotyktu psoriatic arthritis zunsemetinib TAK-279 deucravacitinib NCT04908202 NCT04908189 Aclaris Therapeutics

Related News

clinicaltrialsarena.com

BMS sees success in Phase III Sotyktu psoriatic arthritis trials